



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Application Number	10/606,422
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Filing Date	June 26, 2003
(use as many sheets as necessary)		First Named Inventor	McComsey et al.
Sheet 1 of 2		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	ORT-1222 (DIV)

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>		
DJ		HU	9901290	A	Aventis Pharmaceuticals, Inc.	11-19-1999
DJ		HU	9201875		Merrell Dow Pharmaceuticals, Inc.	6-04-1992
DJ		EP	0503203	A1	Merrell Dow Pharmaceuticals, Inc.	9-15-92 (=HU 9201875)
DJ		WO	92/04371	A1	Ferring Peptide Research Partnership KB	3-19-1992
DJ		WO	99/42475	A1	Ortho-McNeil Pharmaceutical, Inc.	8-26-1999

Examiner Signature	David Luton	Date Considered	1-18-05
-----------------------	-------------	--------------------	---------

*\*and not considered. Include copy of this form with next communication to applicant.*

*1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if applicable.*

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**END OF FORM**  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p><b>Substitute for form 1449A/PTO</b></p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>Sheet 2 of 2</p>	<p><b>Application Number</b> 10/606,422</p> <p><b>Filing Date</b> June 26, 2003</p> <p><b>First Named Inventor</b> McComsey et al.</p> <p><b>Group Art Unit</b></p> <p><b>Examiner Name</b></p> <p><b>Attorney Docket Number</b> ORT-1222 (DIV)</p>
--	---

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
X		Malik Aaser B., "Thrombin-Induced Endothelial Injury", Seminars in Thrombosis and Hemostasis, Vol 12, No. 3, 1986	
X		Cindy L.A. JONES, "Response of a human megakaryocyte cell line to thrombin: Increase in intracellular free calcium and mitogen release", Biochimica et Biophysica Acta, 1136 (1992) 272-282	
X		Ho-Sam AHN, "Structure-Activity Relationships of Pyrazoloquinazolines as Thrombin Receptor Antagonists", Bioorganic & Medicinal Chemistry Letters, 3 (1993) 2073-2078	
DL		Hoekstra, W.J. et al., "Thrombin Receptor (PAR-1) Antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif", Bioorganic & Medicinal Chemistry Letters, GB, Oxford, Vol. 8, No. 13, 7 July 1998, pgs. 1649-1654	
X		Bernatowicz E.A., "Development of potent thrombin receptor antagonist peptides", Journal of Medicinal Chemistry, Vol. 39, 1996, pgs. 4879-4887	
X		McComsey, D.F. et al., "Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1)", Bioorganic & Medicinal Chemistry Letters, GB, Oxford, Vol. 9, No. 10, 17 May 1999, pgs. 1423-1428	
X		Bi-K. Rwang et al., "Enzyme-Catalyzed Peptide Segment Condensation Using 5 (4H)-Oxazolones As Acyl Donors", J. AM. Chem. Soc., Vol. 115, No. 47, 1993, pgs. 7172-7173	
X		David T. Hung et al., "Thrombin-Induced Events in Non-Platelet Cells are Mediated by the Unique Proteolytic Mechanism Established for the Clotted Platelet Thrombin Receptor", The Journal of Cell Biology, Vol. 110, No. 3, Feb. 1992, pp. 827-832.	
X		Kees Jalink et al., "Thrombin Receptor Activation Causes Rapid-Neutrophil Cell Rounding and Neutrite Retraction Independent of Classic Second Messengers", The Journal of Cell Biology, Vol. 118, No. 2, July 1992, pp. 411-419	
DL		Yasuo Sugama et al., "Thrombin-Induced Expression of Endothelial P-Selection and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion", The Journal of Cell Biology, Vol. 119, No. 4, November 1992, pp. 935-944	
X		Thien-Khal & H. Vu et al., "Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation", Cell, Vol. 64, March 1991, pp. 1057-1068	
X		Dimitris N. Tatakis et al., "Thrombin Effects on Osteoblastic Cells- II. Structure-Function Relationships", Biochemical and Biophysical Research Communications, Vol. 174, No. 1, Jan. 1991, pp. 181-188	
X		John M. Harlan et al., "Thrombin Induces Release of Platelet-Derived Growth Factor-Like Molecule(S) by Cultured Human Endothelial Cells", The Journal of Cell Biology, Vol. 103, Sept. 1986, pp. 1129-1133	
X		Michael R. Bevilacqua et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils related to Complement Regulatory Proteins and Lectins", Science, Vol. 243, March 1989, pp. 1160-1164	
X		D.M. Carney et al., "Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor Activating Peptides", The American Society for Clinical Investigation, Inc., Vol. 89, May 1992, pp. 1460-1477	

Examiner Signature Alvind Kellay Date Considered 1-18-05

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.**

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

PATENT & TRADEMARK OFFICE		Application Number	10/606,422
		Filing Date	June 26, 2003
		First Named Inventor	McComsey et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	ORT-1222 (DIV)
SUBMISSION UNDER MPEP 609 D			
Page 1 of 1			

#### **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

Not Considered